Prasugrels farmakokinetik og dets hæmning af trombocytaggregering var ens hos forsøgspersoner med mild til moderat nedsat leverfunktion sammenlignet med raske forsøgspersoner.
Pharmacokinetics of prasugrel and its inhibition of platelet aggregation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects.